| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 800 | ₹0.5 -41.17% | 18,6000% |
| 2,3250% | ₹136.55 0% | 820 | ₹0.65 8.33% | 2,3250% |
| 2,3250% | ₹137.5 14.39% | 840 | ₹0.3 -25% | 44,950-6.45% |
| 7750% | ₹130 0% | 850 | ₹0.6 0% | 20,9250% |
| - | - | 870 | ₹1 0% | 4,6500% |
| - | - | 880 | ₹1.1 0% | 29,4500% |
| 7750% | ₹78.75 0% | 890 | ₹1.5 0% | 35,6500% |
| 12,4000% | ₹83.5 0% | 900 | ₹2 2.56% | 1,21,675-3.08% |
| 3,1000% | ₹60.25 0% | 910 | ₹2 0% | 41,8500% |
| 20,1500% | ₹58.25 0% | 920 | ₹3.75 10.29% | 72,850-3.09% |
| 82,1500% | ₹46.25 0% | 930 | ₹4.8 -1.03% | 67,4250% |
| 98,4250% | ₹43.05 0% | 940 | ₹7.2 10.76% | 1,59,6502.48% |
| 1,46,4751.61% | ₹31.3 -11.2% | 950 | ₹10 12.99% | 1,15,47510.37% |
| 1,75,9250.88% | ₹24.8 -14.33% | 960 | ₹13.05 9.66% | 2,03,0502.74% |
| 1,49,57514.88% | ₹18.85 -16.4% | 970 | ₹17.8 11.59% | 1,35,6251.74% |
| 4,46,4000.69% | ₹14 -19.3% | 980 | ₹22.35 7.71% | 1,03,850-8.84% |
| 2,51,100-4.70% | ₹10 -22.48% | 990 | ₹28.95 10.28% | 50,3751.56% |
| 6,20,000-12.47% | ₹7.3 -23.95% | 1,000 | ₹35.8 8.32% | 1,37,1750.56% |
| 2,13,1250.73% | ₹5 -27.53% | 1,010 | ₹41.05 0% | 8,5250% |
| 1,69,7253.30% | ₹3.5 -29.29% | 1,020 | - | - |
| 93,7753.41% | ₹2.5 -28.57% | 1,030 | - | - |
| 85,250-2.65% | ₹1.7 -27.65% | 1,040 | ₹66 0% | 1,5500% |
| 90,6756.36% | ₹1.35 -20.58% | 1,050 | - | - |
| 2,02,2750% | ₹1.1 0% | 1,060 | - | - |
| 7750% | ₹1 0% | 1,070 | - | - |
| 20,1500% | ₹0.8 0% | 1,080 | ₹125.8 0% | 3,1000% |
| 1,55,0000% | ₹0.4 0% | 1,100 | ₹135.85 0% | 1,5500% |
| 13,9500% | ₹0.75 -6.25% | 1,120 | - | - |
Fortis will take charge of the entire operational and financial aspects. Hence, consolidating the hospital's performance within its network.
Operating performance remained strong with EBITDA rising 43% year-on-year to ₹490.4 crore. The EBITDA margin expanded to 22.6%, from 18.4% a year ago.
The tax demand will not affect the company’s financials or operations, it said in a regulatory filing.
Here are some of the stocks that may see significant price movement today: UltraTech Cement, Jio Financial, Avenue Supermarts, etc.
EBITDA grew 32.1% YoY at ₹375.2 crore v/s ₹284 crore, a period to period, as was the expansion of EBITDA margin at 19.5% versus 16.9% Q3 FY24.
The deal worth ₹429.37 crore involves acquiring 5,970,149 equity shares at an agreed price of ₹719.2 per share through a shareholders' agreement.
Revenue from operations saw a notable growth of 12.3%, reaching ₹1,988.4 Crore, compared to ₹1,770 Crore YoY.
Jacob Ballas and International Finance Corporation (IFC), who together with Resurgence PE own approximately 34% of the diagnostics company.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
